Literature DB >> 18347813

Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases.

Adam D Elkin1, Charlotte D Jacobs.   

Abstract

PURPOSE: Adenoid cystic carcinoma of the salivary gland (ACC-SG) is a slow-growing tumor that is refractory to most chemotherapeutic agents. Estrogen receptor (ER) antagonists provide a novel approach for recurrent disease.
METHODS: We report two cases of ACC-SC in which Tamoxifen/Toremifene were used.
RESULTS: Both patients obtained long-term stability of disease with no associated toxicity.
CONCLUSIONS: Given the relatively unsuccessful treatments for ACC-SC and the low toxicity of ER antagonists, such therapy should be considered in these patients for its potential disease-stabilizing effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347813     DOI: 10.1007/s00432-008-0377-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo.

Authors:  D A McNamara; J Harmey; J H Wang; E Kay; T N Walsh; D J Bouchier-Hayes
Journal:  Eur J Surg Oncol       Date:  2001-12       Impact factor: 4.424

2.  Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models.

Authors:  K L Blackwell; Z A Haroon; S Shan; W Saito; G Broadwater; C S Greenberg; M W Dewhirst
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

3.  Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland.

Authors:  Laura D Locati; Marco Guzzo; Paolo Bossi; Paolo P Brega Massone; Barbara Conti; Elena Fumagalli; Claudia Bareggi; Giulio Cantù; Lisa Licitra
Journal:  Oral Oncol       Date:  2005-10       Impact factor: 5.337

4.  Prognostic factors in major salivary gland cancer.

Authors:  E Hocwald; H Korkmaz; G H Yoo; V Adsay; T Y Shibuya; J Abrams; J R Jacobs
Journal:  Laryngoscope       Date:  2001-08       Impact factor: 3.325

5.  Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin.

Authors:  S Dori; P Trougouboff; R David; A Buchner
Journal:  Oral Oncol       Date:  2000-09       Impact factor: 5.337

6.  Estrogen receptors in normal salivary gland and salivary gland carcinoma.

Authors:  I W Dimery; L A Jones; R P Verjan; A K Raymond; H Goepfert; W K Hong
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-10

7.  Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors.

Authors:  Selim M Nasser; William C Faquin; Yogeshwar Dayal
Journal:  Am J Clin Pathol       Date:  2003-06       Impact factor: 2.493

8.  Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.

Authors:  Stina Garvin; Charlotta Dabrosin
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

Review 9.  Adenoid cystic carcinoma of the head and neck--a 20 years experience.

Authors:  H Kokemueller; A Eckardt; P Brachvogel; J-E Hausamen
Journal:  Int J Oral Maxillofac Surg       Date:  2004-01       Impact factor: 2.789

10.  Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.

Authors:  Y Kang; R Cortina; R R Perry
Journal:  J Natl Cancer Inst       Date:  1996-03-06       Impact factor: 13.506

View more
  8 in total

1.  Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy.

Authors:  N Chooback; Y Shen; M Jones; K Kasaian; M Martin; T Ng; T Thomson; M Marra; J Laskin; C Ho
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

2.  Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: a single institutional experience at a tertiary care center.

Authors:  Anna Marcinow; Enver Ozer; Theodoros Teknos; Lai Wei; Agnes Hurtuk; Matthew Old; Amit Agrawal; Ricardo Carrau; Obiajulu H Iwenofu
Journal:  Head Neck       Date:  2014-02-01       Impact factor: 3.147

Review 3.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

4.  Prognostic value of expression of molecular markers in adenoid cystic cancer of the salivary glands compared with lymph node metastasis: a retrospective study.

Authors:  Seok Ki Lee; Min Su Kwon; Yoon Se Lee; Seung-Ho Choi; Sang Yoon Kim; Kyoung Ja Cho; Soon Yuhl Nam
Journal:  World J Surg Oncol       Date:  2012-12-11       Impact factor: 2.754

5.  Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer.

Authors:  Ryuichi Murase; Tomoki Sumida; Akiko Ishikawa; Rumi Murase; Sean D McAllister; Hiroyuki Hamakawa; Pierre-Yves Desprez
Journal:  Int J Otolaryngol       Date:  2011-11-21

Review 6.  Biological roles and clinical significance of estrogen and androgen receptors in head and neck cancers.

Authors:  Chunhong Qin; Yan Lu; Huimin Zhang; Zhe Zhang; Wei Xu; Shuxin Wen; Wei Gao; Yongyan Wu
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

7.  Multicentre clinicopathological study of adenoid cystic carcinoma: A report of 296 cases.

Authors:  Zheng Huang; Juan Pan; Jiaorong Chen; Shidi Wu; Ting Wu; Haihua Ye; Hongfeng Zhang; Xiu Nie; Changzheng Huang
Journal:  Cancer Med       Date:  2021-01-15       Impact factor: 4.452

8.  Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands.

Authors:  Matthijs H Valstar; Michael Schaapveld; Esther C van den Broek; Marie-Louise F van Velthuysen; Mischa de Ridder; Marjanka K Schmidt; Boukje A C van Dijk; Alfons J M Balm; Ludi E Smeele
Journal:  Cancer Med       Date:  2020-11-28       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.